Gene transfer of cytokine inhibitors into human synovial fibroblasts in the scid mouse model

Arthritis and Rheumatism

Volumn 42, Issue 3, 1999, Pages 490-497

  Müller Ladner, Ulf ^a   Evans, Christopher H ^b   Franklin, Barry N ^c   Roberts, Charles R ^c   Gay, Renate E ^c,d   Robbins, Paul D ^b   Gay, Steffen ^c,d  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARTILAGE CELL; CARTILAGE DEGENERATION; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION REGULATION; GENE TARGETING; GENE TRANSFER; HUMORAL IMMUNITY; INFLAMMATORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROVIRUS; RHEUMATOID ARTHRITIS; SYNOVIUM;

ANIMALS; ANTIGENS, CD; ARTHRITIS, RHEUMATOID; CARTILAGE; CHONDROCYTES; DISEASE MODELS, ANIMAL; DNA PRIMERS; FIBROBLASTS; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; HUMANS; INTERLEUKIN-10; LAC OPERON; MICE; MICE, SCID; MOLONEY MURINE LEUKEMIA VIRUS; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SYNOVIAL MEMBRANE; TRANSDUCTION, GENETIC;

EID: 0344882568     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199904)42:3<490::AID-ANR14>3.0.CO;2-L     Document Type: Article

References (44)

1. Gay S, Gay RE, Koopman WJ. Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: two cellular mechanisms explain joint destruction? Ann Rheum Dis 1993;52:S39-47.
2. Geiler T, Kriegsmann J, Keyszer GM, Gay RE, Gay S. A new model for rheumatoid arthritis generated by engraftment of rheumatoid synovial tissue and normal human cartilage into SCID mice. Arthritis Rheum 1994;37:1664-71.
3. O'Sullivan FX, Gay RE, Gay S. Spontaneous arthritis models. In: Henderson B, Pettipher R, Edwards J, editors. Mechanisms and models in rheumatoid arthritis. London: Academic Press; 1995. p. 471-83.
4. Müller-Ladner U, Kriegsmann J, Franklin BN, Matsumoto S, Geiler T, Gay RE. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 1996;149:1607-15.
5. Müller-Ladner U, Roberts CR, Franklin BN, Gay RE, Robbins PD, Evans CH, et al. Human IL-1Ra gene transfer into human synovial fibroblasts is chondroprotective. J Immunol 1997;158: 3492-8.
6. Nita I, Ghivizzani SC, Galea-Lauri J, Bandara G, Georgescu HI, Robbins PD, et al. Direct gene delivery to synovium: an evaluation of potential vectors in vitro and in vivo. Arthritis Rheum 1996;39: 820-8.
7. Otani K, Nita I, Macaulay W, Georgescu HI, Robbins PD, Evans CH. Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy. J Immunol 1996;156:3558-62.
8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
9. Firestein GS, Yeo M, Zvaifler NJ. Apoptosis in rheumatoid arthritis synovium. J Clin Invest 1996;96:1631-8.
10. Peppel K, Crawford D, Butler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 1991;174:1483-9.
11. 35S- and digoxigenin-labeled RNA and oligonucleotide probes for in situ hybridization. Histochemistry 1992;98:217-28.
12. Koch AE, Kunkel SL, Chensue SW, Haines GK, Stricter RM. Expression of interleukin-1 and interleukin-1 receptor antagonist by human rheumatoid synovial tissue macrophages. Clin Immunol Immunpathol 1992;65:23-9.
13. Arend WP, Dayer J-P. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor a in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
14. Mort JS, Dodge GR, Roughley PJ, Liu J, Finch SJ, DiPasquale G. Direct evidence for active metalloproteinase mediating matrix degradation in interleukin-1 stimulated human articular cartilage. Matrix 1993;13:95-102.
15. Hess EV. Cytokine inhibitors and osteoarthritis. J Rheumatol 1990;17:1123-4.
16. Dodge GR, Poole AR. Immunohistochemical detection and immunohistochemical analysis of type II collagen degradation in human normal, rheumatoid and osteoarthritic articular cartilages and in explants of bovine articular cartilages cultured with interleukin-1. J Clin Invest 1989;83:647-61.
17. Van Lent PLEM, van de Loo FAJ, Holthuysen AEM, van den Bersselaar AM, Vermeer H, van den Berg WB. Major role for interleukin-1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice. J Rheumatol 1995; 22:2250-8.
18. Brennan FM, Maini RN, Feldmann M. TNF alpha - a pivotal role in rheumatoid arthritis. Br J Rheumatol 1992;31:293-8.
19. Probert L, Plows D, Kontogeorgeous G, Kollias G. The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF transgenic mice. Eur J Immunol 1995;25:1794-7.
20. Kalden JR, Manger B. Biologic agents in the treatment of inflammatory rheumatic diseases. Curr Opin Rheumatol 1996;8: 195-200.
21. Van de Loo FAJ, Joosten LAB, van Lent PLEM, Arntz OJ, van den Berg WB. Role of interleukin-1, tumor necrosis factor a, and interleukin-6 in cartilage proteoglycan metabolism and destruction: effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 1995;38:164-72.
22. Rankin ECC, Choy EHS, Kassimos D, Kingsley GH, Sopwith AM, Isenberg DA, et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995;34:334-42.
23. Maini RN, Elliott M, Brennan FM, Williams RO, Feldmann M. Targeting TNFa for the therapy of rheumatoid arthritis. Clin Exp Rheumatol 1994;12:S63-6.
24. Brennan FM, Gibbons DL, Cope AP, Katsikis P, Maini RN, Feldmann M. TNF inhibitors are produced spontaneously by rheumatoid and osteoarthritic synovial joint cell cultures: evidence of feedback control of TNF action. Scand J Immunol 1995;42:158-65.
25. Butler DM, Feldmann M, Di Padova F, Brennan FM. p55 and p75 tumor necrosis factor receptors are expressed and mediate common functions in synovial fibroblasts and other fibroblasts. Eur Cytokine Netw 1994;5:441-8.
26. Grell M, Wajant H, Zimmermann G, Scheurich P. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci U S A 1998;95:570-5.
27. Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β, and IL-IRa. Arthritis Rheum 1996;39:797-809.
28. Mori L, Iselin S, Delibero G, Lesslauer W. Attenuation of collagen induced arthritis in 55 kDa TNF receptor type I (TNFRl) IgG1 treated and TNFR1 deficient mice. J Immunol 1996;157:3178-82.
29. Pretolani M, Goldman M. IL-10, a potential therapy for allergic inflammation. Immunol Today 1997;18:277-80.
30. Cush JJ, Splawski JB, Thomas R, McFarlin JE, Schulze-Koops H, Davis LS, et al. Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis Rheum 1995;38:96-104.
31. Cassatella MA, Meda L, Gasperini S, Calzetti F, Bonora S. Interleukin-10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation. J Exp Med 1994;179:1695-9.
32. Müller-Ladner U, Kriegsmann J, Tschopp J. Gay RE, Gay S. Demonstration of granzyme A and perforin messenger RNA in the synovium of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:477-84.
33. Tak PP, Kummer JA, Hack CE, Daha MR, Smeets TJM, Erkelens GW, et al. Granzyme-positive cytotoxic cells are specifically increased in early rheumatoid synovial tissue. Arthritis Rheum 1994;37:1735-43.
34. Geng Y, Gulbins E, Altmann A, Lotz M. Monocyte deactivation by interleukin-10 via inhibition of tyrosine kinase activity and the Ras signaling pathway. Proc Natl Acad Sci U S A 1994;91:8602-6.
35. Trabandt A, Aicher WK, Gay RE, Sukhatme VP, Fassbender HG, Nilson-Hamilton M. Expression of the collagenolytic and ras-induced cysteine protease cathepsin L and proliferation-associated oncogenes in synovial cells of MRL/1 mice and patients with rheumatoid arthritis. Matrix 1990;10:349-61.
36. Hart PH, Ahern HJ, Smith MD, Finlay-Jones JJ. Comparison of the suppressive effects of interleukin-10 and interleukin-4 on synovial fluid macrophages and blood monocytes from patients with inflammatory arthritis. Immunology 1995;84:536-42.
37. Isomaki P, Luukkainen R, Saario R, Toivanen P, Punnonen J. Interleukin-10 functions as an antiinflammatory cytokinc in rheumatoid synovium. Arthritis Rheum 1996;39:386-95.
38. Van Roon JAG, van Roy JLAM, Gmelig-Meyling FHJ, Lafeber FPJG, Bijlsma JWJ. Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4. Arthritis Rheum 1996;39:829-35.
39. Walmsley M, Katsikis PD, Abney E, Parry S, Williams RO, Maini RN, et al. Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum 1996;39:495-503.
40. Tanaka Y, Otsuka T, Hotokebuchi T, Miyahara H, Nakashima H, Kuga S. Effect of IL-10 on collagen-induced arthritis in mice. Inflamm Res 1996;45:283-8.
41. Moore KW, Vieira P, Fiorentino DF, Trounstine ML, Kahn TA, Mosmann TR. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BRCFI. Science 1990;248: 1230-4.
42. Qui L, Ding Y, Pahud DR, Robson ND, Shaked A, Bromberg JS. Adenovirus-mediated gene transfer of viral interleukin-10 inhibits the immune response to both alloantigen and adenoviral antigen. Hum Gene Ther 1997;8:1365-74.
43. Lyons A, Kelly JL, Rodrick ML, Mannick JA, Lederer JA. Major injury induces increased production of interleukin-10 by cells of the immune system with a negative impact on resistance to infection. Ann Surg 1997;4:450-60.
44. Pelletier J-P, Caron JP, Evans C, Robbins PD, Georgescu HI, Jovanovic D, et al. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum 1997;40:1012-9.